Improved Aerobic Capacity and Adipokine Profile Together with Weight Loss Improve Glycemic Control without Changes in Skeletal Muscle GLUT-4 Gene Expression in Middle-Aged Subjects with Impaired Glucose Tolerance

Mika Venojärvi 1,*, Jaana Lindström 2, Sirkka Aunola 3, Pirjo Nuutila 4 and Mustafa Atalay 5

Abstract: (1) Objective: The aim of this study was to clarify the role of adipokines in the regulation of glucose metabolism in middle-aged obese subjects with impaired glucose tolerance in response to a long-term exercise and dietary intervention. (2) Methods: Skeletal muscle, plasma and serum samples were examined in 22 subjects from an exercise–diet intervention study aiming to prevent type 2 diabetes. The subjects were further divided into two subgroups (non-responders n = 9 and responders n = 13) based on their achievement in losing at least 3 kg. (3) Results: The two-year exercise–diet intervention reduced leptin levels and increased adiponectin levels in responders; the changes in leptin levels were significantly associated with changes in their weights (r = 0.662, p < 0.01). In responders, insulin sensitivity (Bennett and McAuley index) increased and was associated with changes in maximal oxygen uptake (VO\textsubscript{2peak}) (r = 0.831, p < 0.010 and r = 0.890, p < 0.01). In addition, the VO\textsubscript{2peak} and oxidative capacity of skeletal muscle improved in responders, but not in non-responders. However, there were no changes between the two groups in expressions of the glucose transporter protein-4 (GLUT-4) gene or of AMP-activated protein kinase (AMPK)-α1 or AMPK-α2 proteins. (4) Conclusions: The exercise–diet intervention decreased serum leptin and increased serum adiponectin concentrations, improved glucose control without affecting GLUT-4 gene expression in the skeletal muscle in responders.

Keywords: aerobic capacity; glycemic control; impaired glucose tolerance; adipokines; physical activity

1. Introduction

Impaired insulin sensitivity in skeletal muscle is an early defect in the pathogenesis of type 2 diabetes since it can be detected several years before the development of overt diabetes [1]. Insulin resistance in skeletal muscle is associated with an elevated adipose tissue mass [2]. The interplay between adipose tissue and skeletal muscle is important as the body tries to defend itself against insulin resistance in the peripheral tissues; this interplay is regulated by several factors and through more than one pathway [3]. Earlier studies revealed that adipose tissue secretes more than 50 different adipokines into circulation [2], while recent proteomic studies identified even more adipokines being secreted into the circulation and exosomes [4]. It is well-known that several adipokines and cytokines, including adiponectin, leptin, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), INF-γ (interferon-γ) and tumor necrosis factor-α (TNF-α), can influence insulin
signaling in skeletal muscle [3]. The down-regulation of the insulin receptor substrate 1 (IRS-1) pathway by TNF-α and a reduced activation of 5′-AMP activated protein kinase and AMPK (AMP-activated protein kinase) due to leptin resistance have been associated with insulin resistance [5,6]. IL-6 induces the hepatic synthesis of C-reactive protein (CRP) and its levels have been linked with visceral adiposity [7] but its role in obesity and insulin resistance is controversial. Monocyte chemoattractant protein-1 (MCP-1) also aggravates insulin resistance at doses similar to its physiological plasma concentrations (200 pg/mL) [2]. In contrast to the other adipokines, adiponectin concentrations are low in obesity and at the stage of insulin resistance; therefore, adiponectin is considered to be an insulin-sensitizing hormone [8]. Skeletal muscle cytokine expression can be increased via several pathways, including the p38MAPK and NF-κB pathways; this pattern of inflammatory expression seems to depend on the duration of obesity and the stage of type 2 diabetes. It has been reported that the INF-γ pathway is up-regulated in skeletal muscle cells isolated from insulin-resistant type 2 diabetic patients [9]. On the other hand, rodent studies indicated that INF-γ−/− mice displayed better glucose tolerance compared to their wild type counterparts [10].

There are both human and animal studies demonstrating that long-term physical activity increased the expression of the GLUT-4 gene in skeletal muscle in middle-aged active subjects as compared to their sedentary peers [11]. Furthermore, in rats fed a high-fat diet, the expression of the GLUT-4 gene was decreased in skeletal muscle [12]. Nevertheless, as far as we are aware, there is no information on the effects of a long-term exercise–diet intervention on GLUT-4 and IRS-1 gene expression.

Skeletal muscle is a major site of insulin-stimulated glucose disposal [13]. In addition to insulin, physical exercise (i.e., muscle contraction and hypoxia) stimulates the translocation of the glucose transporter protein-4 (GLUT-4) to the plasma membrane. These two stimuli, i.e., insulin and physical exercise, act at least partially via independent pathways. These alternative pathways, which act in an additive manner to insulin-stimulated glucose uptake, could potentially improve the glycemic control of insulin-resistant subjects. AMPK is one of the key players in the pathway stimulated by muscle contraction [14]. The increased ratio of AMP to ATP activates this energy sensor protein, which is heterotrimeric and consists of a catalytic α and regulatory β and γ subunits [15]. The AMPK isoforms α1 and α2 are expressed in skeletal muscle [16] and their activities can be increased by moderate-intensity exercise but not with low-intensity exercise equal to or below 40% of VO2 max [17]. Thus, AMPK also plays a key role in the regulation of fatty acid oxidation in skeletal muscle and it can be activated by adiponectin and leptin, resulting in enhanced fatty acid oxidation and glucose uptake [14]. In addition, the systemic effects of increased AMPK activity are regulated by many factors, i.e., adiponectin, insulin, IL-6, leptin and TNF-α. Understanding how these secreted signaling proteins regulate AMPK activity may yield clues to discovering novel therapeutic strategies for metabolic disorders, such as diabetes, insulin resistance and obesity [15]. It has also been debated whether exercise can improve insulin sensitivity in overweight individuals without accompanying weight loss [18,19]. Dube and co-workers reported that both diet-induced weight loss and exercise training improved insulin resistance in overweight-to-obese adults [18]. Church et al. [20] revealed that, in patients with type 2 diabetes, the combination of aerobic and resistance training improved glycemic control and maximum oxygen consumption when compared to the control group. The same results could not be achieved by either aerobic or resistance training alone [21]. In this study, we explored the effects of a 2-year exercise–diet intervention on glucose metabolism in middle-aged obese subjects with impaired glucose tolerance (IGT) and separately in those who achieved or did not achieve a weight loss during this two-year period. Here, we also report the responses of plasma levels of adipokines and cytokines to our long-term exercise and dietary intervention to provide evidence of new approaches that could be beneficial in the prevention and treatment of type 2 diabetes.
2. Materials and Methods

This is a sub-study of the Finnish Diabetes Prevention Study (DPS), a randomized controlled trial aiming to prevent type 2 diabetes in individuals with IGT at baseline, details of which have been described elsewhere [22,23]. IGT was defined by OGTT (oral glucose tolerance test) [18]. The sub-study was carried out in one of the five study clinics (Turku). Blood samples for metabolic indices were taken at baseline and after 2 years. A maximal exercise test and muscle sampling (with no strenuous exercising during the preceding 2 days) were performed at 6 months and after 2 years. The Ethical Committee of the Hospital of South-West Finland, Turku, Finland and the Ethics Committee of the Rehabilitation Research Centre of the Social Insurance Institution of Finland approved the protocol of the sub-study (25 January 1996). On 6 March 1992, the Ethics Committee of The National Public Health Institute in Helsinki, Finland approved the protocol of the main study, and all the study subjects gave their written informed consent.

2.1. Subjects

A total of 110 obese subjects with impaired glucose tolerance, based on two oral glucose tolerance tests, were randomized to the intervention or the control group in the Turku clinic. Of the intervention group participants, the 22 subjects who volunteered to provide samples from the m. vastus lateralis were included in this study. The subjects were retrospectively divided into two subgroups, non-responders (n = 9) and responders (n = 13) according to their weight loss at the year 2 assessment point. The subgroup of non-responders was composed of subjects in whom weight loss was equal to or less than 1.3 kg (weight change range +3.0 to −1.3 kg; mean ± std +0.33 ± 0.6 kg) and the subgroup of the responders was composed of subjects achieving at least a weight loss of 2.9 kg (range −2.9 to −14.5 kg; mean ± std −7.7 ± 1.0 kg) during the intervention (Figure 1). The characteristics of the subjects are shown in Table 1.

![Graph showing weight loss during the 2-year intervention in the subgroups of responders and non-responders in the IGT subjects.](image_url)
Table 1. Baseline characteristics of the subjects with impaired glucose tolerance (IGT) subdivided into the non-responders and responders.

| Characteristics                        | Non-Responders | Responders | p Value |
|----------------------------------------|----------------|------------|---------|
| n = (Female/Male)                      | 9 (2/6)        | 13 (4/9)   | n.s     |
| Age (years)                            | 57.1 ± 2.3     | 55.1 ± 2.0 | n.s     |
| Height (cm)                            | 174.2 ± 1.5    | 172.6 ± 2.2| n.s     |
| Weight (kg)                            | 89.7 ± 1.8     | 89.7 ± 2.9 | n.s     |
| BMI                                    | 29.5 ± 0.6     | 30.1 ± 0.7 | n.s     |
| WHR                                    | 0.96 ± 0.02    | 0.96 ± 0.02| n.s     |
| **Aerobic performance capacity**       |                |            |         |
| VO2max (L/min)                         | 2.37 ± 0.22    | 2.26 ± 0.18| n.s     |
| VO2peak (mL/kg−1/min)                  | 26.7 ± 2.7     | 26.2 ± 1.9 | n.s     |
| **Muscle fiber type composition**      |                |            |         |
| MHC I                                  | 38.0 ± 3.0     | 37.9 ± 3.3 | n.s     |
| MHC IIA                                 | 41.6 ± 2.7     | 43.4 ± 3.2 | n.s     |
| MHC IIX                                | 21.0 ± 2.7     | 18.7 ± 2.8 | n.s     |
| **Dietary intake**                     |                |            |         |
| Energy intake, kcal/day                | 1823 ± 143     | 1925 ± 169 | n.s     |
| Alcohol, E%                            | 2.6 ± 1.3      | 4.5 ± 1.2  | n.s     |
| Carbohydrates, E%                      | 44.7 ± 2.0     | 42.5 ± 1.8 | n.s     |
| Fat, E%                                | 35.6 ± 1.6     | 35.1 ± 1.1 | n.s     |
| Protein, E%                            | 17.1 ± 1.2     | 17.9 ± 0.7 | n.s     |
| Dietary fiber, g/day                   | 22.3 ± 2.1     | 19.7 ± 1.9 | n.s     |

Data are presented as means ± SE. Kruskal–Wallis test between groups. n.s non-significant, BMI: body mass index, WHR: waist-hip-ratio, MHC: myosin heavy chain, VO2max: maximal oxygen uptake, VO2peak: peak oxygen uptake, E% = percent of energy intake.

2.2. Intervention

The lifestyle intervention started with intensive dietary counselling [24]. After 6 months, a supervised, progressive and individually tailored circuit-type resistance training program started. The main goals of the intervention were as follows: (1) weight reduction of 5% or more, (2) less than 30% of the daily energy intake from fat, (3) less than 10% of the daily energy intake from saturated fat, (4) fiber intake of 15 g per 1000 kcal or more and (5) physical activity at moderate intensity for 30 min or more each day. The implementation of the intervention program was previously reported [23,24]. Briefly, the participants in the intervention group were given detailed and individualized counselling to achieve the lifestyle goals set for them. They had seven individual counselling sessions with a nutritionist during the first year and every three months thereafter. During the first 6 months, the intervention focused on dietary counselling, in order to allow the subjects to concentrate on changing their eating habits. The subjects were also individually encouraged by a nutritionist to increase their physical activity, and later on, to participate both in regular resistance training at a gym as well as undertaking aerobic exercise. After 6 months, a supervised exercise training session arranged twice a week was added to the intervention program, as previously described [25]. The supervised training was progressive and individually designed, consisting mostly of strength and power training in the gym, along with spinning exercises and aerobic gymnastic exercises. The power-type strength training was organized as circuit training. Any physical activity lasting 30 min or longer was recorded by the participants. The subjects were advised to exercise with moderate-to-intense effort for at least 30 min per session and three to four times a week. The content of training program was described in greater detail in our previous report [25].

2.3. Muscle Biopsy

A skeletal muscle biopsy was taken from the vastus lateralis muscle under local anesthesia (lidocaine 10 mg/mL), using the ‘semi-open’ conchotomy technique [26]. Muscle samples were immediately frozen in liquid nitrogen and stored at −80 °C until analysis. Samples for biochemical analyses were thawed in an ice bath, weighed, and homoge-
nized in 1:50 (v/v) of 1 M Tris buffer pH adjusted to 7.5 in a manually operated all-glass homogenizer [27].

2.4. Total RNA Preparation

Total RNA was extracted from ~20 mg of muscle pieces using a mono-phasic solution of phenol and guanidine isothiocyanate (TRIzol® Reagent; Total RNA Isolation Reagent, Life Technologies, GIBCO BRL, Rockville, MD, USA) and chloroform, isopropyl alcohol, 75% ethanol and RNase-free water. The isolated RNA was further purified with the GenElute Mammalian Total RNA kit (Sigma Chemicals, St Louis, MO, USA). The absorption ratio (260:280 nm) varied from 1.6 to 2.0.

2.5. Real Time PCR

The first-strand cDNA was synthesized from 0.1 µg of total RNA using SuperScript™ II RNase H-Reverse Transcriptase (Invitrogen, Waltham, MA, USA, Life Technologies, Carlsbad, CA, USA). Primers and probes (GLUT-4, INF-γ, IRS-1 and TNF-α) were designed using Primer Express software (PE Biosystems, Foster City, CA, USA) (Table 2). Real-time (RT) PCR was performed using the ABI PRISM 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA). The probes were labelled with FAM at the 5′ end as the reporter dye and TAMRA at the 3′ end as the quencher dye. Gene expression of the gene of interest (mRNA) was calculated using the ∆-critical threshold method, normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and expressed as post- vs. pre-values in non-responders and responders [28].

Table 2. List of primers and probes used in the RT-PCR assay.

| Gene       | Probe                 | Forward primer       | Reverse primer        |
|------------|-----------------------|----------------------|-----------------------|
| GAPDH      | 5′-ACCAGCCGCCCCAATACGACCAA-3′ | 5′-GTTCGACATCAGCCGCATC-3′ | 5′-GGAATTTGCCATGGGTGGA-3′ |
| GLUT-4     | 5′-CTC-AGC-CAG-CAC-TCC-AGA-ATC-GG-3′ | 5′-AAG-AGT-CTG-AAG-GGC-CTG-ACA-3′ | 5′-CAG-CTT-CCG-CTC-ATC-CT-3′ |
| INF-γ      | 5′-TGCTGGCGACAGTTCAGCCATCAC-3′ | 5′-CTCGAAACAGCATCTGACTTCTT-3′ | 5′-TGTCGAAAAGCAGATCCTTCAACCTTAAG-3′ |
| IRS-1      | 5′-AAACCCCATTCTCTCATGACACGGTGTTG-3′ | 5′-TCTCCACCAAGCTGAACAGT-3′ | 5′-TGTCGATAAATCTCTTCAACCTTAAG-3′ |
| TNF-α      | 5′-CATCCTTCTGAACCCCGAGTGACAAGC-3′ | 5′-TGCCCAGGCTGACAGT-3′ | 5′-GGTTTGCTACAAACTGGGTCTACA-3′ |

GAPDH: glyceraldehyde-3-phosphate dehydrogenase, INF-γ: interferon-γ, GLUT-4: glucose transporter protein-4, IRS-1: insulin receptor substrate-1, TNF-α: tumor necrosis factor.

2.6. Immunoblotting

One-dimensional sodium dodecyl sulphate polyacrylamide vertical gel electrophoresis was performed to separate proteins according to their molecular weights [25]. The percentage of polyacrylamide was 10%. After separation, proteins were transferred to nitrocellulose membranes (0.45 mm thick, PROTRAN®, San Francisco, CA, USA) in a Bio-Rad trans-blot electrophoretic transfer cell at a constant voltage of 100 V for 1 h. After
protein transfer, the nitrocellulose membranes were blocked for 1 h with 5% non-fat dry milk at +37°C. The blots were incubated overnight at +4°C with the following antibodies: goat polyclonal anti-AMPK-α1 and -AMPK-α2 (Santa Cruz, CA, USA). Horseradish peroxidase-conjugated immunoglobulins were used as secondary antibodies (Santa Cruz, CA, USA). The membranes were developed with an enhanced chemiluminescence method (NEN Life Sciences, Boston, MA, USA) and quantified using image analysis software (NIH-Image, Fredrick, MD, USA). The results were normalized with beta-actin values (LabVision/NeoMarkers, Fremont, CA, USA: MS-742-S0). The protein concentrations were measured from homogenates using the BCA method (Pierce, Rockford, IL, USA) after equal amounts of the protein extract (20 µg) were loaded onto the gels.

2.7. Assessment of Enzyme Activities in the Muscle Samples

The citrate synthase (CS, E.C.4.1.3.7) activity was assayed from 50 µL of the homogenate dilution according to Srere [29]. All preparation steps were performed at 4°C. Enzyme activities were assayed with an Olli-C analyser (Kone Oy, Espoo, Finland).

2.8. Determination of Myosin Heavy Chain Profile

The myosin heavy chain (MHC) isoform composition (MHC I, MHC IIa, MHC IIx) in muscle homogenate was determined by SDS-PAGE gel electrophoresis using a Bio-Rad Protein II Xi vertical slab gel system (Bio-Rad, Hercules, CA, USA) [25].

2.9. Adipokine Assays from Serum Samples

Adiponectin was measured using sandwich ELISA assay according to the manufacturer’s instructions (B-Bridge International, Inc Mountain View; Santa Clara, CA, USA). IL-6, leptin, MCP-1 and TNF-α were simultaneously measured with a BioRad Bio-Plex 200 System using LINCOplex Human Adipokine Panel B according to the manufacturer’s instructions (Millipore, Billerica, MA, USA) [30].

2.10. Blood Chemistry

Plasma glucose was enzymatically analyzed with hexokinase (Olympus System Reagent, Hamburg, Germany), and serum insulin was determined with a radioimmunoassay (Pharmacia, Uppsala, Sweden). The hemoglobin A1c (HbA1c) concentration was assayed using latex immunoagglutination inhibition methodology (DCA, 2000 Reagent Kit, Bayer Corporation, Elkhart, IN, USA). Bennett’s index was calculated with the formula $1/(\ln(fasting\ insulin\ (\mu U/mL) \times\ fasting\ glucose\ (mmol/L))$ [31]; the Homeostasis Model Assessment and insulin resistance (HOMA-IR) were calculated according to the formula: HOMA-IR = fasting serum insulin (µU/mL) × fasting plasma glucose (mmol/L)/22.5 [32]. McAuley’s index was calculated according to the formula $Mffm/I = \exp[2.63 - 0.28 \ln(fasting\ insulin/\mu U/mL) - 0.31 \times \ln(fasting\ triglyceride/mmol/L)]$ [31]. Serum total cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides were determined using enzymatic assay methods (CHOP-PAP, Monotest, Boehringer Mannheim, Germany). The concentrations of free fatty acids were determined using enzymatic colorimetric method, and gamma-glutamyl transferase (GT) was determined by an ECCLS method (Olympus System reagent, Olympus, Hamburg, Germany).

2.11. Exercise Test and Maximal Oxygen Uptake (VO₂max)

A 2 min incremental cycle ergometer test until volitional exhaustion or fatigue of the lower limbs was employed to measure the maximal oxygen uptake (VO₂max). The warm-up loading was 30–40 W for women and 40–60 W for men, depending on the age, size and physical fitness of the subjects. Thereafter, the work rate was increased every second minute with equal increments (10–25 W) throughout the test. The increments were individually determined based on the subject’s physical fitness, so that the maximum work rate would be reached in about 12–15 min [33]. Respiratory gas exchange was measured...
continuously using a breath-by-breath method. \( \text{VO}_2\text{max} \) was recorded as the highest averaged value over 30 s at the work rate maximum [31].

2.12. Assessment of Dietary Intake

Nutrient intakes were assessed using a dietary analysis program developed by the National Public Health Institute [34]. At baseline and before the 24-month visit, the subjects were asked to complete a three-day food record [35,36].

2.13. Statistical Analysis

Data are reported as means ± standard error (SE). Student’s paired t test was used to assess differences within groups (baseline and 2-year intervention) with the Kruskall–Wallis test applied for examining differences between the groups. IBM SPSS statistics software version 27.0 (IBM, Armonk, NY, USA) was used for the statistical analyses. All reported \( p \) values were based on 2-tailed statistical tests, with a significance level set at \( p < 0.05 \). Correlation analyses were performed between changes in the weight loss and \( \text{VO}_2\text{max} \), levels of adiponectin and leptin, citrate synthase activity, Bennett index, McAuley index and HOMA-IR using the Pearson correlation test. The strength of association according to the Pearson correlation coefficient was considered as weak (0.1–0.39), moderate (0.40–0.69), strong (0.7–0.89) or very strong (0.9–1.00). Cohen D was used to determine the effect size for a statistically significant difference within groups and between groups by estimating eta squared based on the H-statistic \((\eta^2) = (H - k + 1)/(n - k)\). The effect size is assessed as follows; small \((d = 0.2)\), medium \((d = 0.5)\) and large \((d ≥ 0.8)\) based on Cohen D; eta squared \((\eta^2)\) is evaluated as follows; small \((0.01–<0.06)\), moderate effect \((0.06–<0.14)\) and large effect \((≥0.14)\).

3. Results

The exercise–diet intervention induced a significant weight reduction during the 2-year follow-up in whole intervention group (\( n = 22 \)) (−4.4 ± 5.0); the change was much greater in the responders (−7.7 ± 1.0) than in the non-responders (−0.3 ± 0.6; \( p < 0.001 \)). In addition, waist–hip ratio (WHR) decreased in the responders as compared to baseline values \((p < 0.01)\) but not in the non-responders (n.s). There was no difference detected in the training activity between the subgroups during the 2-year exercise–diet intervention (Table 3). The proportions of MHC (myosin heavy chain) I, MHC IIA and MHC IIX were similar at baseline (Table 1). The exercise training increased the proportion of MHC I \((p < 0.05)\) and slightly decreased (n.s) the proportion of MHC IIX isoforms in the vastus lateralis muscle in the responders, but this change did not occur in the non-responders. After the 2-year exercise–diet intervention, the proportion of MHC I was significantly higher in the responders than in the non-responders \((p < 0.05)\) (Table 3).

| Table 3. Exercise frequency and changes in muscle fiber composition occurring during 2-year intervention in the IGT subjects. |
|---------------------------------|------------------|------------------|
| Exercise frequency (hours/week) | Non-Responders    | Responders       |
| Moderate and heavy aerobic training | 1.2 ± 0.3        | 1.3 ± 0.3        |
| Strength and power training      | 2.4 ± 0.6        | 1.3 ± 0.2        |
| Walking and lighter aerobic training | 1.7 ± 0.6        | 2.3 ± 0.4        |
| Total amount of training         | 5.4 ± 0.8        | 4.9 ± 0.8        |
| Muscle fiber composition%        |                  |                  |
| δMHC I                          | −1.5 ± 1.4 #     | 3.8 ± 1.7 *      |
| δMHC IIA                        | 1.3 ± 2.0        | 1.0 ± 2.6        |
| δMHC IIX                        | 0.2 ± 2.0        | −4.9 ± 2.8       |

Data are presented as means ± SE; * \( p < 0.05 \) within groups using paired Student t-test; # \( p < 0.05 \) between groups using Kruskal–Wallis test.
3.1. Aerobic Performance

The aerobic capacity was at the same level in both subgroups at the baseline (Table 4). The 2-year intervention increased both maximal oxygen uptake values $\text{VO}_2\text{max}$ and $\text{VO}_2\text{peak}$ ($p < 0.01$ and $p < 0.001$, respectively) and oxidative capacity (CS) ($p < 0.01$) of the muscle tissue in the responders but only $\text{VO}_2\text{max}$ ($p < 0.05$) values in the non-responders (Table 4). Our results display a large effect size for the changes in $\text{VO}_2\text{max}$, $\text{VO}_2\text{peak}$ and CS in the responder group ($d = -1.108, 4.368$ and $-0.879$, respectively).

### Table 4. Aerobic performance capacity and dietary intake at baseline and after the 2-year in IGT subjects.

| Aerobic performance capacity                  | Non-Responders | Responders |
|-----------------------------------------------|----------------|------------|
| CS (\(\mu\)mol/g wet weight muscle tissue)   | 22.9 ± 3.4     | 25.6 ± 3.2 |
| $\text{VO}_2\text{max}$ (L/min)              | 2.37 ± 0.22    | 2.52 ± 0.22*|
| $\text{VO}_2\text{peak}$ (mL/kg/min)         | 26.7 ± 2.7     | 28.1 ± 2.5 |
| Dietary intake                                |                |            |
| Energy intake, kcal/day                       | 1823 ± 143     | 1916 ± 169 |
| Alcohol, E%                                   | 2.6 ± 1.3      | 2.1 ± 1.0  |
| Carbohydrates, E%                             | 44.7 ± 2.0     | 47.0 ± 2.6 |
| Fat, E%                                       | 35.6 ± 1.6     | 33.2 ± 1.3 |
| Protein, E%                                   | 17.1 ± 1.2     | 17.6 ± 1.3 |
| Dietary fiber, g/day                          | 22.3 ± 2.1     | 23.2 ± 2.8 |

Data are presented as means ± SE; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ within groups using paired Student $t$-test. CS: citrate synthase, $\text{VO}_2\text{max}$: maximal oxygen uptake, E% = percent of energy intake.

3.2. Dietary Energy Intake

At baseline, the dietary energy intake was similar in the non-responders and responders. Furthermore, there were no statistically significant differences in dietary intake between these groups after the 2-year exercise–diet intervention (Table 4). In the responders, dietary fiber intake (g) significantly increased as compared to baseline values ($p < 0.05$) and dietary fat intake as a percentage of the total daily energy (E%) decreased from 35.1% to 30.6% ($p < 0.05$) (Table 4), but not in the non-responders.

3.3. Glucose Metabolism

The metabolic indices, i.e., fasting glucose concentration, 2 h glucose, fasting insulin, 2 h insulin, HbA1c and HOMA-IR at baseline were similar in the non-responders and responders. During the 2-year intervention, the fasting glucose concentration, 2 h glucose, fasting insulin, HbA1c and HOMA-IR significantly decreased in the responders, and 2 h insulin tended to decrease (Table 5). Insulin sensitivity (Bennett and McAuley indices) increased in responders ($p < 0.01$) during the intervention. After the 2-year intervention, fasting glucose levels ($\eta^2 = 0.24$) 2 h insulin levels ($\eta^2 = -0.09$), HOMA-IR ($\eta^2 = 0.013$) were significantly lower in the responders than in the non-responders (Table 5), and the Bennett ($\eta^2 = 0.23$) and McAuley ($\eta^2 = 0.32$) indices were significantly higher in the responders than in the non-responders. Effect sizes ($\eta^2$) were large in insulin sensitivity indices and in fasting glucose levels and weaker in 2 h insulin and HOMA-IR in responders. In the non-responders, we detected no significant changes in the levels of fasting glucose, 2 h glucose, fasting insulin, 2 h insulin, HbA1c or HOMA-IR values (Table 5).
Table 5. Effects of a 2-year exercise–diet intervention on parameters reflecting glucose lipid metabolism in the IGT subjects.

|                      | Baseline | 2-Year | Changes | Baseline | 2-Year | Changes |
|----------------------|----------|--------|---------|----------|--------|---------|
| Fs-Ins (µU/mL)       | 16.7 ± 2.7 | 17.0 ± 3.0 | 0.3 ± 2.7 | 16.4 ± 2.1 | 11.2 ± 1.3 | ** -5.2 ± 1.3 |
| 2 h Ins (µU/mL)      | 96 ± 23   | 81 ± 22 | -15 ± 19 | 97 ± 33   | 45 ± 90 | -55 ± 30 |
| HbA1c (%)            | 5.6 ± 0.1 | 5.4 ± 0.1 | -0.2 ± 0.1 | 5.8 ± 0.1 | 5.3 ± 0.1 *** | -0.5 ± 0.1 |
| Fs-Gluc (mmol/L)     | 6.0 ± 0.1 | 6.1 ± 0.2 | 0.1 ± 0.1 | 6.1 ± 0.1 | 5.6 ± 0.1 *** | -0.5 ± 0.1 |
| 2 h Gluc (mmol/L)    | 8.1 ± 0.3 | 7.0 ± 0.8 | -1.1 ± 0.9 | 7.4 ± 0.4 | 6.0 ± 0.4 * | -1.4 ± 0.5 |
| Bennett I            | 0.51 ± 0.02 | 0.52 ± 0.02 | 0.01 ± 0.01 *** | 0.51 ± 0.02 | 0.57 ± 0.02 ** | 0.06 ± 0.01 |
| HOMA-IR              | 4.5 ± 0.8 | 4.6 ± 0.9 | 0.1 ± 0.8 | 4.5 ± 0.6 | 2.8 ± 0.3 ** | -1.7 ± 0.4 |
| McAuley I           | 5.8 ± 0.3 | 5.7 ± 0.4 | -0.2 ± 0.2 *** | 5.6 ± 0.4 | 6.5 ± 0.3 ** | 1.0 ± 0.2 |
| Cholesterol (mmol/L) | 5.3 ± 0.3 | 4.9 ± 0.2 * | -0.4 ± 0.2 | 5.6 ± 0.2 | 5.5 ± 0.3 | -0.1 ± 0.1 |
| LDL (mmol/L)        | 3.5 ± 0.3 | 3.0 ± 0.2 ** | -0.5 ± 0.12 | 3.7 ± 0.3 | 3.5 ± 0.3 | -0.1 ± 0.12 |
| HDL (mmol/L)        | 1.10 ± 0.10 | 1.14 ± 0.10 | 0.05 ± 0.03 | 1.14 ± 0.09 | 1.26 ± 0.09 | 0.11 ± 0.05 |
| Triglyceride (mmol/L)| 1.54 ± 0.15 | 1.76 ± 0.21 | 0.22 ± 0.06 *,** | 1.96 ± 0.24 | 1.55 ± 0.18 * | -0.42 ± 0.13 |
| FFA (mmol/L)       | 0.68 ± 0.07 | 0.47 ± 0.07 | -0.21 ± 0.11 | 0.69 ± 0.07 | 0.47 ± 0.04 ** | -0.22 ± 0.06 |
| γ-GT (IU/L)          | 36.3 ± 3.2 | 31.4 ± 5.0 | -4.9 ± 3.1 | 40.9 ± 5.1 | 31.5 ± 4.5 ** | -9.4 ± 2.9 |

Data are presented as means ± SE; *p < 0.05, **p < 0.01, ***p < 0.001 within groups using paired Student t-test; #p < 0.05, ##p < 0.01 between groups using Kruskal–Wallis test. Fs-Ins: fasting insulin, HbA1c: Haemoglobin A1c, I: index, HOMA-IR: Homeostasis Model Assessment, insulin resistance, Fs-Gluc: fasting glucose concentration, 2 h Gluc: glucose concentration at 2 h of oral glucose tolerance test, LDL: low-density lipoprotein, HDL: high-density lipoprotein, FFA: free fatty acids, γ-GT: γ-glutamyltransferase.

3.4. Lipid Metabolism

At baseline, the profiles of serum lipid metabolites were essentially the same in the non-responders and responders. After the 2-year intervention, serum triglycerides (p < 0.01) and free fatty acid (p < 0.01) levels significantly decreased, whereas HDL cholesterol (p = 0.051) levels tended to increase in the responders (Table 5). Total serum cholesterol and low-density lipoprotein (LDL)-cholesterol concentrations decreased in the non-responders during the intervention (p < 0.05 and p < 0.01, respectively). In addition, total serum cholesterol and LDL-cholesterol values were significantly lower in the non-responders (p < 0.05) as compared to the responders at the end of the 2-year intervention (Table 5).

3.5. Systemic Concentrations of Adipokines

At baseline, the levels of the adipokines in blood (adiponectin, IL-6, leptin, MCP-1 and TNF-α) were similar in the non-responders and responders (Table 6). The exercise–diet intervention increased systemic adiponectin concentrations by 12% while decreasing the leptin concentration by 27% in the responders, whereas in the non-responders the leptin concentration increased by 15%, and the adiponectin concentration decreased by 4% after the 2-year intervention (Table 6). The differential change in leptin levels between groups was statistically significant (p < 0.001, η² = 0.44). There were no statistically significant differences in the systemic concentrations of IL-6, MCP-1 and TNF-α either within or between the groups (Table 6).
Table 6. Effects of a 2-year exercise–diet intervention on the parameters depicting adipokines and cytokines in IGT subjects.

|                | Non-Responders | 2-Year | Changes | Responders | 2-Year | Changes |
|----------------|----------------|--------|---------|------------|--------|---------|
| Adiponectin (µg/mL) | 6.8 ± 1.5 | -0.3 ± 0.5 | 7.6 ± 1.3 | 8.5 ± 1.2 * | 1.0 ± 0.5 | 7.1 ± 1.2 |
| IL-6 (pg/mL)    | 3.5 ± 1.9 | 3.7 ± 2.1 | 0.2 ± 0.3 | 2.9 ± 2.0 | 2.2 ± 1.4 | -0.7 ± 0.6 |
| Leptin (pg/mL)  | 11.7 ± 3.1 | 13.4 ± 3.8 | 1.7 ± 1.0 | 14.2 ± 3.6 | 10.4 ± 3.2 ** | -3.8 ± 1.0 # |
| MCP-1 (pg/mL)   | 348 ± 52 | 307 ± 43 | -41 ± 24 | 279 ± 35 | 291 ± 43 | 11 ± 29 |
| TNF-α (pg/mL)   | 5.4 ± 0.9 | 5.8 ± 1.2 | 0.4 ± 0.5 | 4.5 ± 0.7 | 4.6 ± 0.6 | 0.03 ± 0.5 |

Data are presented as means ± SE; *p < 0.05, **p < 0.01 within groups using paired Student t-test; #p < 0.01 between groups using Kruskal–Wallis test. IL-6: interleukin-6, MCP-1: monocyte chemoattractant protein-1, TNF-α: tumor necrosis factor.

3.6. Cytokine Gene Expression in Skeletal Muscle

We did not detect any difference in the relative change in gene expressions of INF-γ (p = 0.053) or TNF-α between the groups (p = 0.382) (Figure 2).

![Relative changes in the gene expressions of INF-γ, IRS-1, GLUT-4 and TNF-α after the 2-year exercise–diet intervention in the skeletal muscles of the IGT subjects.](image)

Figure 2. Relative changes in the gene expressions of INF-γ, IRS-1, GLUT-4 and TNF-α after the 2-year exercise–diet intervention in the skeletal muscles of the IGT subjects.

3.7. Expression of the Genes for Two Insulin Signaling Mediators in Skeletal Muscle

The expressions of IRS-1 (p = 0.305) or GLUT-4 (p = 0.234) did not differ between the groups after the 2-year exercise–diet intervention (Figure 2).

3.8. AMPK Protein Expression in the Skeletal Muscle

At baseline, the protein expressions of the AMPK-α1 and AMPK-α2 were at same level in the studied subgroups. Due to the intervention, the protein expression of AMPK-α1 tended to increase in the responders (p < 0.10) but not in the non-responders (Figure 3A). The expression of the AMPK-α2 protein remained unchanged in both subgroups after the 2-year intervention (Figure 3B).
Three incident cases of diabetes were diagnosed during five-year follow-up period, 3 in the non-responders group and none in the responders group.

4. Discussion

In this study, at the two-year assessment of an intervention involving an increase in physical activity and a modification of diet, there was evidence of enhanced oxygen uptake (10%), increased oxidative capacity of skeletal muscle (37%) and decreased insulin...
resistance (60%) in the responders. Furthermore, the increased maximal oxygen uptake positively correlated with the improvements in insulin sensitivity. These improvements were associated with a complete prevention of type 2 diabetes as observed in the responders after a 5-year follow-up, while one out of every three of the non-responders (3/9) was diagnosed with type 2 diabetes.

Obesity and physical inactivity are the main non-genetic risk factors for type 2 diabetes [37]. Although increased physical activity and changes in daily dietary habits are the main lifestyle factors recommended for the prevention of type 2 diabetes [38], after weight loss, only 10% of dieters manage to maintain weight loss in the long-term [39]. On the other hand, the DPS (Diabetes Prevention Study) [23] and several other trials have revealed that lifestyle changes can achieve both significant weight losses and improve glucose tolerance in middle-aged obese subjects with impaired glucose tolerance (IGT) [40–42] and that these are accompanied with an increase in the concentration of adiponectin and decrease in those of serum IL-6 and TNF-α [43–45]. In our study, we detected no changes in the serum levels of IL-6 or TNF-α or MCP-1 in either group, although serum adiponectin concentrations did increase in the responders. In contrast, the gene expressions of INF-γ or TNF-α in skeletal muscle did not change due to the intervention. The expression of pro-inflammatory genes was reported to be elevated in skeletal muscle cells of diabetic patients and interferon-γ-induced up-regulation leading to a decrease in insulin-stimulated glucose uptake [46].

In the present study, in the individuals classified as responders to the exercise–diet intervention, serum leptin levels were reduced (27%), serum adiponectin concentrations increased (12%) and glucose control improved without any changes in the lipid metabolism. In a review, Klimcakova et al. [47] concluded that as little as a 1% weight reduction would be enough to achieve a significant decrease in the plasma leptin concentration. Consistent with other reports [48–50], in the present study, the exercise–diet intervention-induced a reduction in serum leptin levels, and this decline was positively correlated with weight loss in the responders. In the other studies, serum leptin decreased by 37% after weight stabilization due to the consumption of a hypocaloric diet for 16 weeks [51], by 21% after a 3-month dynamic strength training program [52] and by 14% after a 6-month program that combined a hypocaloric diet and moderate physical activity [48]. In the study of Auerbach et al., a strong correlation was evident between changes in fat percentage and plasma leptin levels [53].

In the literature, there is still controversy regarding the effects of regular exercise on adiponectin concentrations. An increase in adiponectin concentration was demonstrated in response to weight loss and glitazone therapy, but not after chronic exercise training [54]. According to Madsen et al. [55], a loss of at least 10% body weight is needed to increase systemic levels of total adiponectin. Nonetheless, many investigators reported that adiponectin levels increased in interventions that induced a major weight loss or a significant reduction of visceral fat; in these trials, it seems that weight loss was more efficient than an exercise-based intervention [56]. However, Fatouros et al. [57] reported that, while the leptin concentration was decreased by low-, moderate- and high-intensity resistance training in inactive obese men, in contrast, the adiponectin concentration rose only in the high-intensity training group. These changes seem to be strongly associated with changes in the ratio of muscle and adipose tissue mass. According to Mujumdar et al. [58], a progressive long-term aerobic training (marathon training) increased the adiponectin concentration in middle-aged, overweight, untrained males and females, without affecting the insulin resistance in either group [58]. The exercise intensity in our trial was not as high as in the studies of Fatouros et al. [57] or Mujumdar et al. [58]. Therefore, it is plausible to conclude that the increase in the adiponectin concentration observed in the present study was due to the combined effects of exercise and diet.

Both adiponectin and leptin are hormonal regulators of AMPK signaling and are generally perceived to exert positive effects on insulin sensitivity [15]. The protein expression of AMPK-α1 was increased after one-month’s endurance training in healthy young males.
and in type 2 diabetes patients after 6 weeks of strength training [59,60]. However, in our study, the protein expressions of the AMPK-α1 and AMPK-α2 in the skeletal muscle remained unchanged in both groups after the 2-year intervention, and there was no correlation between the changes in the amounts of the AMPKs and CS. In work conducted in rodents, when AMPK is chronically activated, a similar adaptive pattern of an increase in mitochondrial oxidative enzymes was observed. Nevertheless, our study design did not allow us to investigate either AMPK activity or signaling by this protein in skeletal muscle. However, in skeletal muscle, adiponectin activates both AMPK-α1 and AMPK-α2, while leptin activates only AMPK-α2, resulting in enhanced fatty acid oxidation [61–63]. In addition, AMPK also regulates glucose homeostasis. The acute regulation of skeletal muscle glucose transport by exercise is multifactorial and has been attributed to several signaling pathways, including Ca²⁺-calmodulin-dependent protein kinase (CaMK)II, AMPK and nitric oxide [64]. Here, the diet and exercise intervention did not increase the expression of the GLUT-4 gene in the skeletal muscle of either the non-responders or the responders. During exercise, AMPK activation occurs as a response to the contraction of fast-twitching muscles, triggering an up-regulation of hexokinase II expression, which subsequently increases GLUT-4 gene expression and GLUT-4 translocation [65–67]. In addition, when considering the response to exercise, AMPK and calcium/calmodulin-dependent protein kinases (CaMK)II contribute to the regulation of GLUT-4 expression via histone hyper-acetylation of the GLUT4 promoter and increase GLUT4 transcriptional activity [68]. In summary, the multifaceted regulation of GLUT-4 may explain the failure to detect any difference in GLUT-4 gene expression between responders and non-responders.

It has been shown that physical exercise increases the GLUT-4 content in both healthy controls and subjects with impaired insulin-stimulated glucose uptake [69–72]. In addition, in subjects with type 2 diabetes, GLUT-4 is normally expressed in skeletal muscle [73,74]. Moreover, an inhibition of protein synthesis did not counteract the exercise-mediated increase in muscle insulin sensitivity [75]. Therefore, increased GLUT4 translocation, rather than its expression, seems to lie behind the improvements in insulin’s action post-exercise [76]. Consistent with this hypothesis, we did not find any increase in the expression of the GLUT4 gene in the responders, despite their improved glycemic control and insulin sensitivity. While physical exercise may be able increase mRNA of GLUT4 in healthy and type 2 patients, it seems that the increase in GLUT mRNA is transient, returning to a pre-exercise level within 24 h [77]. Our results can be interpreted as follows—our exercise–diet intervention had not increased the gene expression of GLUT4 by the end of the 2-year intervention, although it did seem that the exercise intensity could have been high enough to transiently induce the expression of GLUT4.

The failure of non-responders to achieve a weight loss and their lower training intensity may be responsible for their unchanged glucose control or serum adipokine concentrations. Interestingly, total cholesterol and LDL-cholesterol levels only decreased in the non-responders, despite the fact that marginal improvements in the dietary intake of fat and fiber occurred only in responders. On the other hand, serum levels of triglycerides and free fatty acid values were decreased in the responders but not in the non-responders. The chronic adaptation to exercise reduced the synthesis of triglycerides, which may have been a response to the enhanced lipid oxidation in trained skeletal muscle. Aerobic exercise was reported to reduce triglycerides, but this effect was only evident with an accompanying energy deficit [78]. In addition, the exercise–diet intervention may have evoked reductions in free fatty acid levels, and this can improve the insulin sensitivity in both liver and skeletal muscle. In these tissues, the intracellular accumulation of lipids (diacylglycerol) impaired insulin signaling [79]. As a limitation, our study design, did not allow us to reliably evaluate the individual impact of the exercise or changes in the effect of dietary habits on weight loss or improved glucose control. When considering glucose metabolism in skeletal muscle, the greatest changes due to dietary counselling were assumed to have occurred by 6 months. While this gives a good view of the changes in the regulation of the skeletal muscle metabolism induced by exercise, it does not allow us to separately distinguish the
individual effects of either exercise or dietary counselling. In addition, in both groups, rather few participants were women, which needs to be considered while interpreting the results. Although we did not observe any difference between female and male subjects in the changes occurring in any of the parameters, because of the small sample size, we could not perform a more detailed statistical analysis. Dietary intake and the total amount of exercise did not significantly differ between responders and non-responders, but the intensity of the exercise might have been higher in responders (based on their increased citrate synthase activity), and this could contribute, at least partly, to these favorable effects, together with dietary modifications such as increased fiber intake and decreased fat intake. There was no difference in the total duration of physical activity, but the amount of exercise training in responders that consisted of two hours aerobic exercise and one hour strength and power exercise per week may be an optimal strategy to improve metabolism and achieve greater caloric expenditure. It seems that the sustained weight loss achieved by dietary modifications with a combination of aerobic and power-type strength exercises is likely to be the major contributor to the improved glucose control evident in the responders. There can be at least three possible explanations to account for the improved glucose control in the responders. The exercise–diet intervention: (1) reduced body weight with decreased adipose tissue mass resulting in a change to a more favorable adipokine profile; (2) the increased oxidative capacity of skeletal muscle coupled with increased fatty acid oxidation in the skeletal muscle, which reduces leptin resistance and increases adiponectin concentrations; and (3) the reduced level of the hepatic lipid content and weight-loss-related improvements of HOMA-IR, triggering decreased glucose production in liver and a loss of intra-hepatic lipids.

While this study had a strong focus on adipokines and cytokines in middle-aged obese subjects with impaired glucose tolerance, it is important to consider the clinical significance of the findings since dietary counselling and physical activity were the main approaches applied in the prevention and treatment of type 2 diabetes. This two-year exercise–diet intervention exerted a significant effect on fasting glucose levels and insulin sensitivity in responders. Insulin sensitivity is not a basic or standard clinical measurement, but it is an important health outcome that can be easily calculated using routine laboratory values. The extent of weight loss was also clinically significant in the responders (>5%), and together with the improvements of maximal oxygen uptake (large effect size), these changes can be considered to underpin the positive alterations in glucose metabolism evident in the responders. It has been claimed that even a minor weight loss should be enough to significantly decrease plasma leptin levels [47], and in our study, the observed effect size of the changes of leptin was large. The weight loss is an important factor accounting for the decrease in the leptin levels, i.e., it correlated strongly with changes in the serum leptin concentration in responders leading to decreased leptin resistance. The observed effect size shows that successful weight loss and improved aerobic capacity can achieve clinically significant changes in glucose control.

5. Conclusions

In conclusion, an exercise–diet intervention decreased serum leptin levels, increased serum adiponectin concentrations and improved glucose control without affecting cholesterol metabolism or GLUT-4 expression in the skeletal muscle specimens obtained from the individuals who responded well to the intervention.

Author Contributions: M.V. and S.A. designed the study. M.V. and M.A. acquired and analyzed the data, M.V., S.A. and M.A. interpreted the data. M.V. drafted the manuscript. J.L., S.A., P.N. and M.A. critically revised the article. The corresponding author attests that all authors meet authorship criteria and that no others meeting the criteria have been omitted. M.V. is the guarantor. All authors have read and agreed to the published version of the manuscript.
Funding: Research Council for Physical Education and Sports, the Finnish Ministry of Education, the Juho Vainio Foundation, Turku University of Applied Sciences R&D program and the COST Action CA16112.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Hospital District of South-West Finland, Turku, Finland and the Ethics Committee of the Rehabilitation Research Centre of the Social Insurance Institution of Finland approved the protocol of the sub-study (25 January 1996). The Ethics Committee of The National Public Health Institute in Helsinki, Finland on 6 March 1992 approved the protocol of the main study.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: The authors express their gratitude to Minna Glad and Taina Vihavainen for excellent technical assistance and to Arja Kylläinen for her assistance in statistical analyses. They also thank Saku Ruohonen for help with RT-PCR analyses and Osmo Hänninen, Jukka Marniemi, Jukka-Pekka Halonen and Ayyan Korkmaz for excellent comments about this study.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Koistinen, H.A.; Zierath, J.R. Regulation of glucose transport in human skeletal muscle. Ann. Med. 2002, 34, 410–418. [CrossRef] [PubMed]
2. Sell, H.; Dietze-Schroeder, D.; Eckel, J. The adipocyte–myocyte axis in insulin resistance. Trends Endocrinol. Metab. 2006, 17, 416–422. [CrossRef] [PubMed]
3. Romero, A.; Eckel, J. Organ Crosstalk and the Modulation of Insulin Signaling. Cells 2021, 10, 2082. [CrossRef] [PubMed]
4. Hartwig, S.; De Filippo, E.; Göddeke, S.; Knebel, B.; Kotzka, J.; Al-Hasani, H.; Roden, M.; Lehr, S.; Sell, H. Exosomal proteins constitute an essential part of the human adipose tissue secretome. Biochim. Biophys. Acta Proteins Proteom. 2019, 1867, 140172. [CrossRef] [PubMed]
5. Kirwan, J.P.; Jing, M. Modulation of Insulin Signaling in Human Skeletal Muscle in Response to Exercise. Exerc. Sport Sci. Rev. 2002, 30, 85–90. [CrossRef]
6. Dyck, D.J. Leptin Sensitivity in Skeletal Muscle Is Modulated by Diet and Exercise. Exerc. Sport Sci. Rev. 2005, 33, 189–194. [CrossRef]
7. Jaganathan, R.; Ravindran, R.; Dhanasekaran, S. Emerging Role of Adipocytokines in Type 2 Diabetes as Mediators of Insulin Resistance and Cardiovascular Disease. Can. J. Diabetes 2018, 42, 446–456. [CrossRef]
8. Yanai, H.; Yoshida, H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int. J. Mol. Sci. 2019, 20, 1190. [CrossRef]
9. Brown, A.E.; Palsgaard, J.; Borup, R.; Avery, P.; Gunn, D.A.; De Meyts, P.; Yeaman, S.J.; Walker, M. p38 MAPK activation upregulates proinflammatory pathways in skeletal muscle cells from insulin-resistant type 2 diabetic patients. Am. J. Physiol. Endocrinol. Metab. 2015, 308, E63–E70. [CrossRef]
10. Wong, N.; Fam, B.C.; Cempako, G.R.; Steinberg, G.R.; Walder, K.; Kay, T.W.; Proietto, J.; Andrikopoulos, S. Deficiency in Interferon-γ Results in Reduced Body Weight and Better Glucose Tolerance in Mice. Endocrinology 2011, 152, 3690–3699. [CrossRef]
11. Lee, J.S.; Bruce, C.R.; Tunstall, R.J.; Cameron-Smith, D.; Hügel, H.; Hawley, J. Interaction of exercise and diet on GLUT-4 protein and gene expression in Type I and Type II rat skeletal muscle. Acta Physiol. Scand. 2002, 175, 37–44. [CrossRef] [PubMed]
12. Bunprajun, T.; Henriksen, T.I.; Scheele, C.; Pedersen, B.K.; Green, C.J. Lifelong Physical Activity Prevents Aging-Associated Insulin Resistance in Human Skeletal Muscle Myotubes via Increased Glucose Transporter Expression. PLoS ONE 2013, 8, e66628. [CrossRef] [PubMed]
13. DeFronzo, R.A.; Gunnarsson, R.; Björkman, O.; Olsson, M.; Wahren, J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J. Clin. Investig. 1985, 76, 149–155. [CrossRef] [PubMed]
14. Long, Y.C.; Zierath, J.R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Investig. 2006, 116, 1776–1783. [CrossRef]
15. Dzamko, N.L.; Steinberg, G.R. AMPK-dependent hormonal regulation of whole-body energy metabolism. Acta Physiol. 2009, 196, 115–127. [CrossRef]
16. Janzen, N.R.; Whitfield, J.; Hoffman, N.J. Energy Sensing to Interactive Roles for AMPK and Glycogen from Cellular Exercise Metabolism. Int. J. Mol. Sci. 2018, 26, 3344. [CrossRef]
17. Chen, Z.-P.; Stephens, T.J.; Murthy, S.; Canny, B.J.; Hargreaves, M.; Witters, L.A.; Kemp, B.E.; McConnell, G.K. Effect of Exercise Intensity on Skeletal Muscle AMPK Signaling in Humans. Diabetes 2003, 52, 2205–2212. [CrossRef]
18. Boule, N.G.; Weisnagel, S.J.; Lakka, T.A.; Tremblay, A.; Bergman, R.N.; Rankinen, T.; Leon, A.S.; Skinner, J.S.; Wilmore, J.H.; Rao, D.C.; et al. Effects of exercise training on glucose homeostasis: The HERITAGE Family Study. Diabetes Care 2005, 28, 108–114. [CrossRef]

19. Finucane, F.M.; Sharp, J.S.; Purtslow, L.R.; Horton, K.; Horton, J.; Savage, D.B.; Brage, S.; Besson, H.; De Lucia Rolfe, E.; Sleigh, A.; et al. The effects of aerobic exercise on metabolic risk, insulin sensitivity and intrahepatic lipid in healthy older people from the Hertfordshire Cohort Study: A randomised controlled trial. Diabetologia 2010, 53, 624–631. [CrossRef]

20. Dubé, J.J.; Amati, F.; Toledo, F.G.; Stefanovic-Racic, M.; Rossi, A.; Coen, P.; Goodpaster, B.H. Effects of weight loss and exercise on insulin resistance, and intramyocellular triacylglycerol, diacylglycerol and ceramide. Diabetologia 2011, 54, 1147–1156. [CrossRef]

21. Church, T.S.; Blair, S.N.; Cocoreham, S.; Johannsen, N.; Johnson, W.; Kramer, K.; Mikus, C.R.; Myers, V.; Nauta, M.; Rodarte, R.Q.; et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: A randomized controlled trial. JAMA 2010, 304, 2253–2262. [CrossRef] [PubMed]

22. Eriksson, J.; Lindström, J.; Valle, T.; Aunola, S.; Hamalainen, H.; Ilanne-Parikka, P.; Keinanen-Kiukaanniemi, S.; Laakso, M.; Lauhkonen, M.; Lehto, P.; et al. Prevention of Type II diabetes in subjects with impaired glucose tolerance: The Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention pro-grammme. Diabetologia 1999, 42, 793–801. [CrossRef]

23. Tuomilehto, J.; Lindström, J.; Eriksson, J.G.; Valle, T.T.; Hämaalainen, H.; Ilanne-Parikka, P.; Keinanen-Kiukaanniemi, S.; Laakso, M.; Louheranta, A.; Rastas, M.; et al. Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N. Engl. J. Med. 2001, 344, 1343–1350. [CrossRef] [PubMed]

24. Lindström, J.; Louheranta, A.; Mannelin, M.; Rastas, M.; Salminen, V.; Eriksson, J.; Uusitupa, M.; Tuomilehto, J. Finnish Diabe tes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003, 26, 3230–3236. [PubMed]

25. Venojarvi, M.; Puhke, R.; Hamalainen, H.; Marniemi, J.; Rastas, M.; Rusko, H.; Nuutila, P.; Hanninen, O.; Aunola, S. Role of skeletal muscle-fibre type in regulation of glucose metabolism in middle-aged subjects with impaired glucose tolerance during a long-term exercise and diet intervention. Diabetes Obes. Metab. 2005, 7, 745–754. [CrossRef]

26. Henriksson, K.G. “Semi-open” muscle biopsy technique. A simple outpatient procedure. Acta Neurol. Scand. 1979, 59, 317–323. [CrossRef]

27. Aunola, S.; Marniemi, J.; Alanen, E.; Mäntylä, M.; Saraste, M.; Rusko, H. Muscle metabolic profile and oxygen transport capacity as determinants of aerobic and anaerobic thresholds. Eur. J. Appl. Physiol. Occup. Physiol. 1998, 75, 726–734. [CrossRef] [PubMed]

28. Osler, M.E.; Fritz, T.; Caidahl, K.; Krook, A.; Zierath, J.R.; Wallberg-Henriksson, H. Changes in Gene Expression in Responders and Nonresponders to a Low-Intensity Walking Intervention. Diabetes Care 2015, 38, 1154–1160. [CrossRef] [PubMed]

29. Srere, P.A. [I] Citrate synthase:[EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acylating)]. In Methods in Enzymology; Academic Press: Cambridge, MA, USA, 1969; pp. 3–11.

30. Venojarvi, M.; Wasenius, N.; Mänderoos, S.; Heinonen, O.J.; Hernelahiti, M.; Lindholm, H.; Surakka, J.; Lindström, J.; Aunola, S.; Atalay, M.; et al. Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glu-cose regulation. Ann. Med. 2013, 45, 162–170. [CrossRef]

31. McAuley, K.A.; Williams, S.M.; Mann, J.I.; Walker, R.J.; Lewis-Barned, N.J.; Temple, L.A.; Duncan, A.W. Diagnosing Insulin Resistance in the General Population. Diabetes Care 2001, 24, 460–464. [CrossRef]

32. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28, 412–419. [CrossRef]

33. Surakka, J.; Alanen, E.; Aunola, S.; Karppi, S.-L.; Pekkarinen, H. Effects of External Light Loading in Power-type Strength Training on Muscle Power of the Lower Extremities in Middle-aged Subjects. Int. J. Sports Med. 2007, 28, 448–455. [CrossRef] [PubMed]

34. Ovaskainen, M.-L.; Valsta, L.M.; Lauronen, J. The compilation of food analysis values as a database for dietary studies—The finnish experience. Food Chem. 1996, 57, 133–136. [CrossRef]

35. Haapa, E.; Toponen, T.; Pietinen, P.; Räsänen, L. Annoskuvakirja; Painokari Oy: Helsinki, Finland, 1985.

36. Pietinen, P.; Hartman, A.M.; Haapa, E.; Rasani, L.; Haapakoski, J.; Palmgren, J.; Albanes, D.; Virtamo, J.; Huttunen, J.K. Reproducibility and validity of dietary assessment instruments. I. A self-administered food use questionnaire with a portion size picture booklet. Am. J. Epidemiol. 1988, 128, 655–666. [CrossRef] [PubMed]

37. Ling, C. Epigenetic regulation of insulin action and secretion—Role in the pathogenesis of type 2 diabetes. J. Intern. Med. 2020, 288, 158–167. [CrossRef]

38. Kolb, H.; Martin, S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes. BMC Med. 2017, 15, 131. [CrossRef]

39. National Task Force on the Prevention and Treatment of Obesity Overweight. Obesity, and health risk. Arch. Intern. Med. 2000, 160, 898–904. [CrossRef]

40. Pan, X.-R.; Li, G.-W.; Hu, Y.-H.; Wang, J.-X.; Yang, W.-Y.; An, Z.-X.; Hu, Z.-X.; Lin, J.; Xiao, J.-Z.; Cao, H.-B.; et al. Effects of Diet and Exercise in Preventing NIDDM in People with Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 1997, 20, 537–544. [CrossRef]
41. Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E.; Hamman, R.F.; Lachin, J.M.; Walker, E.A.; Nathan, D.M.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med.* 2002, 346, 393–403. [CrossRef]

42. Uusitupa, M.; Khan, T.A.; Vigiliouk, E.; Kahleova, H.; Rivellese, A.A.; Hermansen, K.; Pfeiffer, A.; Thanopoulou, A.; Salas-Salvadó, J.; Schwab, U.; et al. Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis. *Nutrients* 2019, 11, 2611. [CrossRef]

43. Esposito, K.; Pontillo, A.; Di Palo, C.; Giugliano, G.; Masella, M.; Marfella, R.; Giugliano, D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. *JAMA* 2003, 289, 1799–1804. [CrossRef] [PubMed]

44. Jung, S.H.; Park, H.S.; Kim, K.S.; Choi, W.H.; Ahn, C.W.; Kim, B.T.; Kim, S.M.; Lee, S.Y.; Ahn, S.M.; Kim, Y.K.; et al. Effect of weight loss on serum cytokines in human obesity: Increase in IL-10 after weight loss. *Nutr. Biochem.* 2008, 19, 371–375. [CrossRef] [PubMed]

45. Das, U.N. Anti-inflammatory nature of exercise. *Nutrition* 2004, 20, 323–326. [CrossRef] [PubMed]

46. Brown, A.E. Increased Inflammatory Gene Expression in Skeletal Muscle Cells from Insulin Resistant Type 2 Diabetic Patients. In Proceedings of the 71st Scientific Sessions Insulin Action—Insulin Resistance In Vitro, San Diego, CA, USA, 24–28 July 2011.

47. Klimcakova, E.; Kovacikova, M.; Langin, D. Adipokines and dietary interventions in human obesity. *Obes. Rev.* 2010, 11, 446–456. [CrossRef]

48. Monzillo, L.U.; Hamdy, O.; Horton, E.S.; Ledbury, S.; Mullooly, C.; Jarema, C.; Porter, S.; Ovalle, K.; Moussa, A.; Mantzoros, C.S. Effect of Lifestyle Modification on Adipokine Levels in Obese Subjects with Insulin Resistance. *Obes. Rev.* 2003, 11, 1048–1054. [CrossRef]

49. Monti, V.; Carlson, J.J.; Hunt, S.C.; Adams, T.D. Relationship of Ghrelin and Leptin Hormones with Body Mass Index and Waist Circumference in a Random Sample of Adults. *J. Am. Diet. Assoc.* 2006, 106, 822–828. [CrossRef]

50. Rostás, I.; Potó, L.; Mátrai, P.; Hegyi, P.; Tenk, J.; Garami, A.; Illes, A.; Sólymar, M.; Pétervári, E.; Szűcs, Á.; et al. In middle-aged and old obese patients, training intervention reduces leptin level: A meta-analysis. *PLOS ONE* 2017, 12, e0182801. [CrossRef]

51. Petersen, K.F.; Dufour, S.; Befroy, D.; Lehrke, M.; Hendler, R.E.; Shulman, G.I. Reversal of Nonalcoholic Hepatic Steatosis, Hepatic Insulin Resistance, and Hyperglycemia by Moderate Weight Reduction in Patients with Type 2 Diabetes. *Diabetes* 2005, 54, 603–608. [CrossRef]

52. Klimcakova, E.; Polak, J.; Moro, C.; Hejnova, J.; Majercik, M.; Viguerie, N.; Berlan, M.; Langin, D.; Stich, V. Dynamic strength training improves insulin sensitivity without altering plasma levels and gene expression of adipokines in subcutaneous adi-pose tissue in obese men. *J. Clin. Endocrinol. Metab.* 2006, 91, 5107–5112. [CrossRef]

53. Auerbach, P.; Nordby, P.; Bendtsen, L.Q.; Mehlsen, J.L.; Basnet, S.K.; Vestergaard, H.; Ploug, T.; Stallknecht, B. Differential effects of endurance training and weight loss on plasma adiponectin multimers and adipose tissue macrophages in younger, moderately overweight men. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2013, 305, R490–R498. [CrossRef]

54. Kriketos, A.D.; Gan, S.K.; Poynten, A.M.; Furler, S.M.; Chisholm, D.J.; Campbell, L.V. Exercise increases adiponectin levels and insulin sensitivity in humans. *Diabetes Care* 2004, 27, 629–630. [CrossRef] [PubMed]

55. Madsen, E.L.; Rissanen, A.; Bruun, J.M.; Skogstrand, K.; Tonstad, S.; Hougaard, D.M.; Richelsen, B. Weight loss larger than 10% is needed for general improvement of levels of markers of circulating and inflammation in obese subjects: A 3-year weight loss study. *Eur. J. Endocrinol.* 2008, 158, 179–187. [CrossRef] [PubMed]

56. Christiansen, T.; Paulsen, S.K.; Bruun, J.M.; Ploug, T.; Pedersen, S.B.; Richelsen, B. Diet-Induced Weight Loss and Exercise Alone and in Combination Enhance the Expression of Adiponectin Receptors in Adipose Tissue and Skeletal Muscle, but Only Diet-Induced Weight Loss Enhanced Circulating Adiponectin. *J. Clin. Endocrinol. Metab.* 2010, 95, 911–919. [CrossRef] [PubMed]

57. Fatouros, I.G.; Tournis, S.; Leontsini, D.; Jamurtas, A.Z.; Sxina, M.; Thomakos, P.; Manousaki, M.; Douroudos, I.; Taxildaris, K.; Mitrakou, A. Leptin and Adiponectin Responses in Overweight Inactive Elderly following Resistance Training and Detraining Are Intensity Related. *J. Clin. Endocrinol. Metab.* 2005, 90, 5970–5977. [CrossRef]

58. Mujumdar, P.P.; Duersken-Hughes, P.J.; Firek, A.F.; Hessinger, D.A. Long-term, progressive, aerobic training increases adiponectin in middle-aged, overweight, untrained males and females. *Scand. J. Clin. Lab. Investig.* 2011, 71, 101–107. [CrossRef]

59. Langfort, J.; Viese, M.; Ploug, T.; Dela, F. Time course of GLUT4 and AMPK protein expression in human skeletal muscle during one month of physical training. *Scand. J. Med. Sci. Sports* 2003, 13, 169–174. [CrossRef]

60. Wojsatzewski, J.F.; Birk, J.B.; Freisig, C.; Holten, M.; Pilegaard, H.; Dala, F. 5’AMP activated protein kinase expression in human skeletal muscle: Effects of strength training and type 2 diabetes. *J. Physiol.* 2005, 564, 563–573. [CrossRef]

61. Steinberg, G.R.; Parolin, M.L.; Heigenhauser, G.J.; Dyck, D.J. Leptin increases FA oxidation in lean but not obese human skeletal muscle: Evidence of peripheral leptin resistance. *Am. J. Physiol. Endocrinol. Metab.* 2002, 283, E187–E192. [CrossRef]

62. Tomas, E.; Tsao, T.S.; Saha, A.K.; Murrey, H.E.; Zhang, C.C.; Itani, S.I.; Lodish, H.F.; Ruderman, N.B. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. *Proc. Natl. Acad. Sci. USA* 2002, 99, 16309–16313. [CrossRef]

63. Yamauchi, T.; Kamon, J.; Minokoshi, Y.; Ito, Y.; Waki, H.; Uchida, S.; Yamashita, S.; Noda, M.; Kita, S.; Ueki, K.; et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat. Med.* 2002, 8, 1288–1295. [CrossRef]
64. Jessen, N.; Goodyear, L.J. Contraction signaling to glucose transport in skeletal muscle. *J. Appl. Physiol.* 2005, 99, 330–337. [CrossRef] [PubMed]

65. Holmes, B.F.; Kurth-Kraczek, E.J.; Winder, W.W. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. *J. Appl. Physiol.* 1999, 87, 1990–1995. [CrossRef] [PubMed]

66. Derave, W.; Ai, H.; Ihlemann, J.; Kristiansen, S.; Richter, E.A.; Ploug, T. Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle. *Diabetes* 2000, 49, 1281–1287. [CrossRef] [PubMed]

67. Wright, D.C.; Geiger, P.C.; Holloszy, J.O.; Han, D.H. Contraction- and hypoxia-stimulated glucose transport is mediated by a Ca²⁺-dependent mechanism in slow-twitch rat soleus muscle. *Am. J. Physiol. Endocrinol. Metab.* 2005, 288, E1062–E1066. [CrossRef] [PubMed]

68. Richter, E.A.; Hargreaves, M. Exercise, GLUT4, and skeletal muscle glucose uptake. *Physiol. Rev.* 2013, 93, 993–1017. [CrossRef]

69. Dela, F.; Handberg, A.; Mikines, K.J.; Vinten, J.; Galbo, H. GLUT-4 and insulin receptor binding and kinase activity in trained human muscle. *J. Physiol.* 1993, 469, 615–624. [CrossRef]

70. Dela, F.; Ploug, T.; Handberg, A.; Petersen, L.N.; Larsen, J.J.; Mikines, K.J.; Galbo, H. Physical training increases muscle GLUT4 protein and mRNA in patients with NIDDM. *Diabetes* 1994, 43, 862–865. [CrossRef]

71. Hughes, V.A.; Fiatarone, M.A.; Fielding, R.A.; Kahn, B.B.; Ferrara, C.M.; Shepherd, P.; Fisher, E.C.; Wolfe, R.R.; Elahi, D.; Ev-ans, W.J. Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance. *Am. J. Physiol.* 1993, 264, E855–E862. [CrossRef]

72. Henriksen, E.J. Invited review: Effects of acute exercise and exercise training on insulin resistance. *J. Appl. Physiol.* 2002, 93, 788–796. [CrossRef]

73. Handberg, A.; Vaag, A.; Damsbo, P.; Beck-Nielsen, H.; Vinten, J. Expression of insulin regulatable glucose transporters in skeletal muscle from type 2 (non-insulin-dependent) diabetic patients. *Diabetologia* 1990, 33, 625–627. [CrossRef]

74. Garvey, W.T.; Maianu, L.; Hancock, J.A.; Golichowski, A.M.; Baron, A. Gene expression of GLUT4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM, and NIDDM. *Diabetes* 1992, 41, 465–475. [CrossRef] [PubMed]

75. Fisher, J.S.; Gao, J.; Han, D.H.; Holloszy, J.O.; Nolte, L.A. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. *Am. J. Physiol. Endocrinol. Metab.* 2002, 282, E18–E23. [CrossRef] [PubMed]

76. Hansen, P.A.; Nolte, L.A.; Chen, M.M.; Holloszy, J.O. Increased GLUT-4 translocation mediates enhanced insulin sensitivity of muscle glucose transport after exercise. *J. Appl. Physiol.* 1998, 85, 1218–1222. [CrossRef] [PubMed]

77. Flores-Opazo, M.; McGee, S.L.; Hargreaves, M. Exercise and GLUT4. *Exerc. Sport Sci. Rev.* 2020, 48, 110–118. [CrossRef]

78. Maraki, M.; Sidossis, L.S. Effects of energy balance on postprandial triacylglycerol metabolism. *Curr. Opin. Clin. Nutr. Metab. Care* 2010, 13, 608–617. [CrossRef]

79. Samuel, V.T.; Petersen, K.F.; Shulman, G.I. Lipid-induced insulin resistance: Unravelling the mechanism. *Lancet* 2010, 375, 2267–2277. [CrossRef]